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Abstract
Objective: Adrenomedullin (ADM) and adiponectin are both involved in inflammation and cardiovascular diseases. The
plasma levels of these peptides are influenced by single nucleotide polymorphisms (SNPs) in the ADM and ADIPOQ genes
respectively. There is some evidence that ADM may regulate adiponectin gene expression, but whether adiponectin can
regulate ADM expression is unclear, and was therefore investigated.
Methods: Plasma ADM level was measured in 476 subjects in the Hong Kong Cardiovascular Risk Factor Prevalence Study-2
(CRISPS2). We genotyped them for 2 ADIPOQ SNPs that are known to be associated with plasma adiponectin level.
Results: The minor allele frequencies of ADIPOQ SNPs rs182052 and rs12495941 were 40.6% and 42.2% respectively. Plasma
ADM level was significantly associated with rs182052 after adjusting for age and sex (b= 0.104, P = 0.023) but not with
rs12495941 (b= 0.071, P = 0.120). In multivariate analysis, plasma ADM level increased with the number of minor alleles of
rs182052 (P = 0.013). Compared to subjects with GG genotype, subjects with AA genotype had 17.7% higher plasma ADM
level (95% CI: 3.6%–33.7%). Subgroup analysis revealed that the association was significant in diabetic patients (b= 0.344,
P = 0.001) but not in non-diabetic subjects.
Conclusion: Plasma ADM level is related to SNP rs182052 in the ADIPOQ gene. Our findings provide new evidence of the
interplay between these two important peptides in cardiovascular disease and diabetes. Knowing the genotype may help to
refine the interpretation of these biomarkers.
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Introduction
Adipose tissue is now recognized as a key endocrine organ
which secretes hormones known as adipokines [1]. One of these is
adiponectin, which has insulin-sensitizing effect by promoting lipid
b-oxidation and hepatic gluconeogenesis [2]. It is thought to
counteract insulin resistance and its serum level is decreased in
obesity and type 2 diabetes [3].
Recently, adrenomedullin (ADM) has also been recognized as
an adipokine [4]. ADM is a 52-amino acid peptide and its
plasma level is elevated in many clinical conditions including
hypertension, septic shock, renal failure and in type 2 diabetes
[5,6]. While plasma ADM level is elevated in these pathological
conditions, it is also partly influenced by genetic variation.
Previously our group has reported that the plasma level of
ADM is associated with its single nucleotide polymorphism
(SNP) (rs4910118) [7], and SNP in the interleukin-6 gene
(rs17147230) [8]. In this study we hypothesized that plasma
ADM level might also be affected by genetic variations in the
gene encoding adiponectin. This gene, known as the ADIPOQ
gene, is located in the chromosome 3q27 region. Previous
studies have shown that adiponectin SNPs are associated with
the components of the metabolic syndrome [9,10]. Recently,
our group has also confirmed that ADIPOQ gene variants are
associated with hypertension and adiponectin levels in a Chinese
sample [11].
Since ADM and adiponectin are both secreted from adipose
tissues and are related to the metabolic syndrome, they can be
related in other ways. A previous study has shown an
association between plasma adiponectin level and mid-region
pro-adrenomedullin level (MR-proADM) [12]. It has also been
reported that ADM decreases ADIPOQ gene expression in
epididymal fat [13]. Whether the ADIPOQ gene may affect
ADM level is not clear. Therefore we aimed to investigate the
association between ADIPOQ SNPs and plasma ADM level.
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e70335
Methods
Subjects
The subjects included came from the Hong Kong Cardiovas-
cular Risk Factor Prevalence Study (CRISPS), which is a cohort
study of cardiovascular risk factors in Hong Kong Chinese [14,15].
Initially, 2895 subjects were recruited in 1995–1996 (CRISPS1),
and 1944 of them were followed up in 2000–2004 (CRISPS2) after
a median interval of 6.4 years. The study protocol was approved
by the Ethics Committee of the University of Hong Kong and the
Institutional Review Board of the Hong Kong West Cluster of
Hospitals. All subjects had given written consents. Plasma ADM
levels were measured in 476 subjects who were randomly chosen
from the cohort of 1944 subjects [7,8].
SNP Selection
Tagging SNPs from the ADIPOQ gene were selected from the
HapMap Han Chinese (phase II data, release 24). Using the
HapMap data, 14 ADIPOQ SNPs were identified in our previous
study [11], which were located within 5-kb region upstream to 2-
kb downstream of the gene (position 188,038,157–188,060,946)
with r2$0.9 and minor allele frequency (MAF) $0.05. Four of the
SNPs were found to be significantly associated with plasma
adiponectin level. The association was the strongest in two SNPs,
rs182052 and rs12495941 (P,0.0001) [11]. Therefore in this
analysis we chose to focus on these two SNPs to investigate their
correlation with plasma ADM level. The SNPs were genotyped
using the MassARRAY system (Sequenom, San Diego, CA, USA)
with the iPLEX assay in the Genome Research Centre, The
University of Hong Kong.
Plasma ADM Levels and Other Variables of Interest
Plasma samples were extracted and ADM levels were measured
by radioimmunoassay (RIA) using a method adapted from our
laboratory previously [16]. The immunoreactivity of plasma ADM
was measured by commercially available kits from Peninsula
Laboratories (Belmont, CA, USA) in 235 subjects and Phoenix
Pharmaceuticals (Burlingame, CA, USA) in 241 subjects, using the
same protocol with internal controls to ensure comparability.
Other clinical parameters such as glucose, insulin and lipid profiles
were measured as previously described [14,15,17]. Serum IL-6,
soluble tumor necrosis factor alpha receptor 2 (TNF-a R2), high-
sensitivity C-reactive protein (hsCRP) and adiponectin were
measured from stored samples collected at CRISPS2 with
standard protocols which were previously described [18]. Regular
drinking was defined as alcohol consumption for at least once a
week. Current smoking was defined as smoking at least one
cigarette every week. Regular exercise was defined as having
exercise for at least once a week in past month. Diabetes
associations were adjusted using different models. Since adipo-
nectin is associated with obesity, insulin resistance, hypertension,
inflammation and non-alcoholic fatty liver diseases [20,21],
therefore in model 3 we adjusted for the markers related to these
conditions. Adiponectin level is also associated with lifestyle factors
such as smoking and physical exercise [22], so in model 4 we
further adjusted for 3 lifestyle factors (status of regular smoking,
alcohol drinking, and frequency of exercise).
Statistical Analysis
Regression analysis was performed using SPSS 19.0 for
Windows (SPSS Inc, Chicago, IL, USA). Normally distributed
variables were expressed as means 6 SD, while those with skewed
distributions were natural log-transformed and expressed as
geometric means (95% confidence interval). For variables that
were highly correlated such as BMI and waist circumference, only
one was allowed in the regression model at any one time. Multiple
linear regression models were used to estimate the regression
coefficients. Correction for multiple testing was performed using
permutation test with the simulation repeated 1,000 times.
Linkage disequilibrium was assessed using PLINK software
(version 1.0.7) [23]. The P value for interaction was estimated
by including a multiplicative interaction term in the multivariate
model after adjusting for the main effects of the covariates. Clinical
characteristics of subjects with or without diabetes mellitus were
compared using independent t-test or Chi Square test.
Results
Genotyping of ADIPOQ SNPs and Subject Characteristics
The MAFs of rs182052 and rs12495941 were 40.6% and 42.2%
respectively. Both SNPs were in Hardy Weinberg equilibrium
(P= 0.48 and 0.45 for rs182052 and rs12495941 respectively). The
pairwise linkage disequilibrium (r2) was 0.429.
Table 1 shows the characteristics of the 476 subjects with
plasma ADM levels according to the genotypes of rs182052 and
rs12495941. Both rs182052 and rs12495941 were significantly
associated with adiponectin level in this cohort (P#0.002). The
minor allele of SNP rs182052 was associated with lower
adiponectin levels while that of rs12495941 was associated with
higher adiponectin levels. Also both SNPs were associated with
LDL-cholesterol. The minor allele of SNP rs182052 was
associated with higher LDL-cholesterol levels (P = 0.01) while the
minor allele of rs12495941 was associated with lower LDL-
cholesterol levels (P = 0.008). There is no significant interaction of
plasma ADM levels with sex (P.0.05), so the association was
analyzed in the whole population.
Association of ADIPOQ SNPs with Plasma ADM Level
Figure 1 shows the plasma ADM levels in subjects with different
genotypes in rs182052. There was a significant association
between number of minor allele of rs182052 and plasma ADM
levels (b=0.104, P= 0.023 after adjusting for age and sex). The
association remains significant after adjusting for different
biochemical markers (model 3) and lifestyle factors (model 4),
suggesting that the association was independent of these covariates
(Tables 2 and 3). However, rs12495941 was not significantly
associated with ADM level (b=0.076, P= 0.097 after adjusting for
age and sex).
In a separate analysis, ADIPOQ SNPs were used as categorical
variables in multivariate analysis (Table 2). Presence of two minor
A alleles in rs182052 resulted in a 17.7% increase (95% CI: 3.6%,
33.7%) in plasma ADM level (P = 0.013). The increase in plasma
ADM level was more significant after adjusting for other clinical
parameters (20.0%, 95% CI: 4.8%–37.3%, P= 0.009).
Table S1 shows the subject characteristics according to diabetes
status. There was a significant interaction between the minor allele
of rs182052 and diabetes status after adjusting for their main
effects (P = 0.001). The association between rs182052 and ADM
levels was more significant in subjects with diabetes mellitus
(b=0.344, P= 0.001 after adjusting for age and sex). 12.3% of the
variation in ADM level could be explained by the presence of the
minor allele of rs182052 in diabetic patients after adjusting for age
and sex (Table S2). In contrast, the association of the minor allele
of rs12495941 with ADM level was weaker and not significant in
non-diabetic subjects (b=0.027, P = 0.596 after adjusting for age
and sex).
ADIPOQ SNP and Plasma ADM Level
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Figure 1. A diagram showing plasma ADM levels with different genotypes in rs182052. The error bars represent mean 695% CI. P values
were calculated using natural log-transformed levels after adjusting for age and sex.
doi:10.1371/journal.pone.0070335.g001
Table 2. Multivariate analysis of rs182052 with plasma ADM level (ln-transformed).
Model
Model 1
(n =476)
Model 2
(n =476)
Model 3
(n=424)
Model 4
(n=398)
Additive Model b* 0.100 0.104 0.118 0.114
r2 0.026 0.027 0.046 0.031
Pˆ 0.029 0.023 0.022 0.026
Genotypic Model (with reference to GG
genotype)
AA B** (SE) 0.161 (0.065) 0.163 (0.065) 0.181 (0.069) 0.175 (0.073)
P 0.014 0.013 0.009 0.018
AG B** (SE) 0.026 (0.047) 0.033 (0.048) 0.033 (0.050) 0.040 (0.053)
P 0.583 0.492 0.509 0.459
*Standardized regression coefficient is shown.
**Unstandardized regression coefficient is shown.
‘P values remain significant after permutation test for 1000 times (P,0.05).
Model 1: Unadjusted model.
Model 2: Adjusted for age and sex only.
Model 3: Further adjusted for biochemical parameters including waist circumference, LDL cholesterol, SBP, fibrinogen and natural log of triglycerides, HOMA-IR, fasting
glucose level, hsCRP, adiponectin, interleukin-6, TNF-a R2, ALP and GGT.
Model 4: Further adjusted for lifestyle factors such as regular drinking, smoking and exercise.
doi:10.1371/journal.pone.0070335.t002
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Discussion
A negative association between IL6 SNP and plasma ADM
levels has been demonstrated in our previous study [8]. The
present report was the first to highlight an association between
ADM and adiponectin in human. Since both IL-6 and adiponectin
take part in inflammation, the associations of plasma ADM levels
with IL6 and ADIPOQ SNPs suggests that ADM levels are
regulated by inflammatory factors and its elevation in diabetes and
cardiovascular diseases could be due to inflammation that is
known to occur in these diseases.
ADM and adiponectin are both hormones with well-recognized
roles in the cardiovascular disease and diabetes. ADM is a
vasodilatory peptide that has an important role in the cardiovas-
cular system in health and in disease states. Plasma ADM level is
elevated in hypertension, heart failure, acute myocardial infarc-
tion, atherosclerosis and type 2 diabetes [24,25,26]. The biological
properties of ADM such as vasodilation, hypotension and anti-
oxidation suggest that the elevated level may act as a compensa-
tory response to cardiovascular diseases. Also a stable form of
ADM, MR-proADM could act as a prognostic marker to predict
mortality and survival of patients with heart failure and coronary
heart diseases [27]. One study reports that it is even superior to
CRP and adiponectin in predicting future cardiovascular events
[28].
In contrast, adiponectin is an adipokine the level of which is
lowered in cardiometabolic diseases. Decreased level is observed in
type 2 diabetes, the metabolic syndrome [20], endothelial
dysfunction and coronary heart disease [29,30]. Adiponectin has
cardiovascular protective effects [31]. It protects against endothe-
lial dysfunction and hypertension, and directly acts on cardiomy-
ocytes to protect the heart from ischaemic injury and hypertrophy
[32,33]. Given the important roles of ADM and adiponectin in
cardiovascular diseases, knowing the interactions between these
two peptides may help to refine the interpretation of the levels of
these biomarkers, and may even suggest new therapeutic
approaches in combating these diseases.
Various genetic association studies have demonstrated that the
ADIPOQ gene is associated with plasma adiponectin level [34,35].
Our group has reported that the minor allele of rs182052 was
significantly associated with lower adiponectin level while the
minor allele of rs12495941 was significantly associated with higher
level [11]. However only the minor allele of rs182052 was
significantly correlated with plasma ADM level and the association
was independent of plasma adiponectin level (Table 3). Figure 2
summarizes the interplay between adiponectin and ADM based
on findings from this study and previous studies. Adiponectin and
ADM could regulate each other in 3 ways: 1. The adiponectin
SNP rs182052 could interact with ADM SNP since we previously
showed that ADM SNPs could influence plasma ADM level [7]; 2.
ADM could directly increase adiponectin gene expression and
secretion in vitro [13]; 3. In type 2 diabetes, plasma adiponectin
level tends to be lower [36], while plasma ADM level tends to be
higher [6].
Although both rs182052 and rs12495941 are located in intron 1
of ADIPOQ, rs12495941 is not involved in any putative
transcription binding site, whereas presence of the minor allele
of rs182052 results in the loss of Sp1 binding site and the gain of a
CCAAT/enhancer binding protein (C/EBP) b binding site, both
of which promotes adipocyte differentiation [37]. Since ADM is
highly expressed in differentiated adipocytes [38], further studies
are required to show whether an increase in ADM is due to
enhanced expression from differentiated adipocytes.
Previous studies have demonstrated the roles of ADM and
adiponectin in inflammation. ADM expression is increased in
inflammation prior to administration of endotoxin [39]. It has
both pro-inflammatory and anti-inflammatory actions in macro-
phages and modulates cytokine response [40]. It can also stimulate
release of inflammatory mediators like migratory inhibitory factor
(MIF) and IL-1b while suppressing tumor-necrosis factor alpha
(TNF-a). In contrast, adiponectin exhibits anti-inflammatory
effects [41]. It inhibits TNF-a production and NF-kB activation,
as well as stimulates production of anti-inflammatory cytokines
[42]. Adiponectin also inhibits macrophage activation and both
leptin- and lipopolysaccharide–induced production of pro-inflam-
matory cytokines in macrophages [43]. A recent study suggested
that ADM increased IL-6 expression and the latter decreased
adiponectin expression. Hence, IL-6 might mediate the inhibitory
effect of ADM on adiponectin expression [13]. However, in the
present study the association between adiponectin SNP and ADM
level was not confounded by IL-6. The interaction between
adiponectin and ADM in inflammation deserves further investi-
gation.
The SNP rs182052 was reported to be significantly associated
with type 2 diabetes in an Asian sample [44]. Although the role of
ADM in diabetes has not been well established, elevated plasma
ADM levels were observed in diabetic patients [37]. The stratified
analysis in the present study further showed that diabetes could
influence the association between rs182052 and ADM level, as a
greater effect size (b=0.344) was demonstrated in diabetic
patients. However the limitation of our study was the small
sample size of diabetic patients with low statistical power and
precision. Further studies with a larger sample size are needed to
confirm this finding.
Table 3. Association of covariates with plasma ADM level (ln-
transformed).
Variables b** P value
rs182052 0.114 0.026
Age (years) 20.059 0.355
Sex 20.055 0.405
Waist circumference (cm) 0.101 0.163
SBP (mmHg) 20.023 0.698
Triglycerides (mmol/L)* 20.015 0.807
LDL cholesterol (mmol/L) 20.046 0.390
Fasting glucose (mmol/L)* 20.006 0.923
HOMA-IR* 20.023 0.757
Adiponectin (mg/L)* 0.055 0.351
Fibrinogen (g/L) 0.042 0.483
CRP (mg/L)* 0.073 0.238
GGT (U/L)* 0.040 0.507
ALP (U/L)* 20.111 0.070
IL-6 (pg/L)* 20.098 0.074
TNF-a R2 (pg/mL)* 20.030 0.603
Current smoking (%) 0.005 0.931
Regular drinking (%) 20.032 0.550
Regular exercise (%) ,0.001 0.996
*Variables with skewed distribution were natural log transformed before
analysis.
**Standardized regression coefficient beta was shown.
doi:10.1371/journal.pone.0070335.t003
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In the present study, carriers of minor allele A at rs182052 had
significantly higher LDL-cholesterol level while carriers of minor
allele T at rs12495941 had significantly lower LDL-cholesterol
level (P#0.01) (Table 1). A recent study reported that serum
adiponectin may be inversely correlated with LDL [45]. Since the
minor allele of rs182052 is negatively associated with adiponectin,
while minor allele of rs12495941 is positively associated with
adiponectin, this could account for the opposite trend in the two
SNPs with LDL. It is well known that high LDL level is associated
with higher risk of atherosclerosis and coronary artery disease
(CAD) [46]. Hence the former group of subjects had potentially
higher risk of atherosclerosis and CAD.
In conclusion, this study has demonstrated a significant
association between ADIPOQ SNP rs182052 and plasma ADM
level. This enhances our understanding of the regulation of ADM
level and points to the close interplay between these two hormones
that could be very important in cardiovascular diseases. Further
studies are necessary to elucidate the function of the ADIPOQ SNP
and how it could influence ADM level.
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